Answers are grounded in this paper and cite their sources.
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are expected to be synergistic with intraperitoneal (IP) immunotherapy by increasing tumor antigen expression and mutational load. We assessed the feasibility and safety of IP nivolumab following complete CRS and HIPEC in pretreated patients with recurrent ovarian cancer (ClinicalTrials.gov identifier: NCT03959761).
No takes yet. Share an insight, caveat, or question.
Corbaux et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: